Latest News and Press Releases

Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020       -       A Phase 3 study concludes that a simplified regimen of...

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...

Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare...

3B Future Health Fund announces new investment in iOnctura MONACO, PRINCIPALITY OF MONACO, July 14, 2020:  3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today...

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss...

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...

Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...

Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, June 8, 2020: Helsinn, a Swiss...

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...